The latest technology in Sleep Apnea treatment is the Continuous Positive Airway Pressure (or CPAP) device. It is estimated that only 2,000 new CPAP devices were installed in 2011. This compares to the estimated more than 18.0 million people that the Sleep Apnea Foundation estimates suffer from Sleep Apnea.
The biggest obstacle to treatment is simply that patients do not use the CPAP device regularly. The goal of Sanomedics is to provide patients with access to in-home licensed care practitioners who
specialize in treating respiratory patients. These practitioners will customize the device to fit comfortably on the patient.
SIMH is an early stage medical technology incubator for disruptive and game changing ideas – a place where physicians, entrepreneurs, companies and investors work together to drive innovative technologies through concept, development, and ultimately commercialization.
We rapidly transform accepted concepts into promising new products by providing an incomparable combination of leadership, an experienced, multi-disciplinary team, state-of-the-art engineering and manufacturing relationships supported by an extensive physician network. SIMH is comprised of veteran medical device entrepreneurs and physicians with real world experience—and success—in developing best in class medical device products.
-from the website
None of the products currently available in Argentina utilize our unique and proprietary chemical compounds, which contain antimicrobial agents and compounds to fight the invertebrate iridescent virus, and its interaction with the Nosema fungus, components to contrast the side effects of neonicotinoids used in pesticides. In addition, the current accepted practice advocated by associations of entomologists and apiarists and cooperatives of beekeepers is to avoid the use of antibiotics in treating bees and CCD-related problems. The BeesFree proprietary chemical compound does not contain antibiotics and also yields a high concentration of isoleucine, an amino acid commonly used by Argentine beekeepers to nourish their bees colonies.
WEST PALM BEACH, Fla., Feb. 16, 2012 (GLOBE NEWSWIRE) -- BeesFree, Inc. (OTCBB:BEES.OB - News) today announced that the Company has filed a Technology Patent with Argentinean authorities regarding its innovative technology which aims to mitigate the effects of Colony Collapse Disorder (CCD) and potentially serve as a cure to CCD.
More and more frequently, Honeybees have been mysteriously disappearing across the planet and vanishing from their hives. Known as Colony Collapse Disorder or CCD, this phenomenon has created a crisis within in the beekeeping community, a critical industry responsible for a majority of the world's fruit and vegetable production. In fact, commercial honeybee operations pollinate crops that make up one out of every three bites of food on our nation's tables.
BeesFree CEO Mario Sforza stated, "Now that we have formally filed the patent application in Argentina, we are able to ramp up our aggressive marketing and sales programs. The market in the Argentina bee community is quite large and our discussions with local beekeepers have been quite promising. We look forward to introducing our solutions across all of South America beginning with Argentina."
This patent pending technology is designed to work and be effective on a global scale as honeybees' physiology and behavioral patterns are quite similar across different environmental and climatic conditions. BeesFree has previously filed a global patent surrounding this technology, but as Argentina is not a member of the Patent Cooperation Treaty (PCT), the Company filed for PCT extension with the local Patent Office on February 14, 2012. BeesFree is represented by Laura Berti & CIA, an international law firm located in Buenos Aires that specializes in Intellectual Property Right (IPR) issues.
BeesFree is a unique conglomerate of researchers, beekeepers, businessmen and financiers who leveraged early recognition of a global honeybee problem known as Colony Collapse Disorder into the first known, commercially viable cure for the condition. BeesFree's patent pending formula and delivery system are presently the only products available to combat the phenomenon in a global market whose size measures between $2 and $3 billion. The company's Headquarters are in the US and its corporate laboratories in Rome, Italy. The Company has developed a global marketing strategy currently focused on South America, South Africa, China, India and where its initial product launch will be met with a less restrictive regulatory regime.
About BeesFree, Inc. (OTCBB:BEES.OB - News)
BeesFree is a technology company with global reach, which develops and commercializes innovative solutions for the beekeepers communities on a worldwide scale. For more information, please visit www.beesfree.biz.
The writer notes: "The e-book race between Barnes & Noble, Amazon.com, Apple, Sony, and Google just got a whole lot messier. Amazon, Apple, Sony, Google, and Barnes & Noble are now neck-deep in the game.... but what's the game, what's the score, and who's taking the lead?..."
The writer notes re: STEM: "Market capitalization currently stands at 144.81M, accompanied by an EPS of -0.18. StemCells Inc. is trading at a price of $1.14 per stock, decreasing by 2.56% since it opened this morning at a price of $1.20. StemCells has shown a pretty steady trend with a few fluctuations int he month of November..."